Monoclonal Antibody to Neuraminidase (NEU)
| Code | Size | Price |
|---|
| MAB611Hu21-20ul | 20ul | £85.00 |
Quantity:
| MAB611Hu21-100ul | 100ul | £156.00 |
Quantity:
| MAB611Hu21-200ul | 200ul | £210.00 |
Quantity:
| MAB611Hu21-1ml | 1ml | £480.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
NEU1; SIAL1; Sialidase 1; Lysosomal Sialidase; Acetylneuraminyl hydrolase; G9 sialidase; N-acetyl-alpha-neuraminidase 1
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Neuraminidase
Potency (Clone Number):
2#
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:500-2000<br/>Immunohistochemistry: 5-20ug/mL;1:50-200<br/>Immunocytochemistry: 5-20ug/mL;1:50-200<br/>Optimal working dilutions must be determined by end user.
References
- http://www.freepatentsonline.com/y2020/0239512.html" - METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Neuraminidase (NEU) | RPB611Hu02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||